Mobenakin

Drug Profile

Mobenakin

Alternative Names: Interleukin-1 beta mutein; OCT 43

Latest Information Update: 15 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nonindustrial source
  • Developer Chiron Corporation; Otsuka Pharmaceutical
  • Class Interleukins
  • Mechanism of Action Granulocyte colony stimulating factor stimulants; Granulocyte macrophage colony stimulating factor agonists; Interleukin 1 inhibitors; Macrophage colony stimulating factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer; Glioma; Lymphoma; Urogenital cancer

Most Recent Events

  • 18 Feb 1997 Preregistration for Lymphoma in Japan (SC)
  • 20 Nov 1995 OCT 43 is now called mobenakin
  • 02 Nov 1995 Investigation in Glioma in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top